Hepatitis C in the WHO European Region

Transcription

1 Hepatitis C in the WHO European Region Antons Mozalevskis WHO Regional Office for Europe Drug-related infectious disease (DRID) annual expert meeting June 2015, EMCDDA Lisbon

2 Burden of viral hepatitis C in the WHO European Region Estimated number of people living with infection 1 : Hepatitis C -14 million Over 60% infected live in eastern European and central Asian countries (EECA) Estimated number of deaths due to viral hepatitis 2 : deaths due to Hep C annually Absolute majority due to sequelae (cirrhosis, HCC) 1 V.D. Hope et al. Epidemiol. Infect (2013) Global Disease Burden Estimate

3 Hepatitis C among most affected population groups in the WHO European Region, % 44% Hepatitis C 40% 30% 20% 10% 11% 4% 2% 0% People who inject drugs Men who have sex with men Sex workers General population V.D. Hope et al. Epidemiol. Infect (2013) 1-17

4 Geographical/epidemiological division of the WHO European Region

5 Estimated Anti-HCV and HCV-RNA prevalence in general population (WHO-EURO) Anti-HCV prevalence HCV-RNA prevalence Viraemic rate 2013 population (millions) Anti-HCV infected (millions) HCV-RNA infected (millions) Central Europe 1.3% 1.0% 80% Eastern Europe 3.3% 2.3% 69% Western Europe 0.9% 0.6% 70% Gower E. Et al. Global epidemiology and genotype distribution of the hepatitis C virus. J Hepatology 2014; 61 (suppl 1)

6 Estimated Anti-HCV prevalence in general adult population (WHO-EURO, ) 1 V.D. Hope et al. Epidemiol. Infect (2013) 1-17

7 Estimated Anti-HCV prevalence in people who inject drugs (WHO-EURO, ) 1 V.D. Hope et al. Epidemiol. Infect (2013) 1-17

8 WHO-EURO Centralised information system for infectious disease (CISID) Objectives: to provide a standardised, timely and complete picture of the epidemiology of important infectious diseases; to allow sharing of data at the subnational level to identify specific geographic areas of risk and risk groups by age and gender; Content: WHO/Europe infectious disease data set, compiled from reports submitted by Member States

9

10 CISID data from Joint Reporting Form(JRF) National focal point reporting on the yearly bases (March May) Data sent in Excel (Section 1 & 3) or Word (Section 2) format Section 1 vaccine preventable diseases Section 2 sexually transmitted infections Section 3 other infections including viral hepatitis Data entered by the information management team or by relevant programme staff

11 CISID data from JRF Hepatitis C - Number of cases

12 JRF data on hepatitis C from 2014 (as of ) Out of 53 WHO-EURO Member States reports from 40 MS Andorra zero cases France, Germany, San Marino and Spain no data on hepatitis C Reported cases of viral hepatitis from 35 MS 20 EU/EEA Member States 15 non-eu/eea Member States

13 n=93 737

14 Reported HCV cases (n=93 737) WHO-EURO, 2014 [CATEGO RY NAME] [PERCEN TAGE] [CATEGO RY NAME] [PERCEN TAGE] [CATEGO RY NAME] [PERCEN TAGE]

15 Reported HCV cases (n=93 737) WHO-EURO, 2014 [CATEGO RY NAME] [PERCEN TAGE] [CATEGO RY NAME] [PERCEN TAGE] [CATEGO RY NAME] [PERCEN TAGE]

16 Reported HCV cases outside EU/EEA (n=72 456) Reporting non EU/EEA countries PWID unknown total Albania 0 44 Armenia Azerbaijan Belarus 2789 Bosnia and Herzegovina Georgia Kazakhstan Montenegro Republic of Moldova Russian Federation Serbia Switzerland Tajikistan The former Yugoslav Republic of Macedonia Turkmenistan 2 Total

17 Hepatitis C data in the WHO European Region «Space for imrovement» I ECDC enhanced viral hepatitis surveillance Standartised case definitions (gradually adopted by EU/EEA Member States) Data completness is poor but improving Case reporting should be complemented by serosurveys and data on chronic hepatitis disease sequelae

18 Hepatitis C data in the WHO European Region «Space for imrovement» II WHO-EURO «Joint Reporting Form» Case definition harmonisation (ECDC case definition?) Ways to get rid of double reporting (ECDC and WHO-EURO) Data verification and analysis

19 Hepatitis C data in the WHO European Region «Space for imrovement» III Linking with EMCDDA DRID data? Updated review of published seroprevalence study data? Enhancing the network of the national viral hepatitis focal points

20 WHO Regional Office for Europe Contact: Antons Mozalevskis, WHO-EURO focal point for viral hepatitis: Martin Donoghoe, WHO-EURO regional advisor on HIV/AIDS & hepatitis:

21 Thank you